BioSpace

ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 411th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. Live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer.

Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancer AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.

Agency will use the software platform to support modern cosmetic safety assessment through integrated exposure and toxicity modeling. RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc.

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors. “We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise.

CALGARY, Alberta--(BUSINESS WIRE)--BioAlberta is honoured to announce the recipients of the 2026 Achievement Awards at the Health and Life Sciences Showcase and Awards Dinner in Calgary on September 24th, 2026. This year’s award recipients exemplify the leadership in health innovation and technology that are developed in Alberta’s life sciences ecosystem.

Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development Innovation Center is part of Roche and Genentech’s $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in...

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027 The Company has voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies; patients currently enrolled in the ongoing studies remain active...